The duration of remission for B-ALL patients who relapsed after allo-HSCT treated with donor-derived anti-CD19 CAR-T cells was only 1-22 months and the overall survival time was only 2-22 months (16, 24–26). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.